Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2008

01.06.2008 | Clinical Trial

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

verfasst von: Mario Campone, Loïc Campion, Henry Roché, Wilfried Gouraud, Catherine Charbonnel, Florence Magrangeas, Stéphane Minvielle, Jean Genève, Anne-Laure Martin, Régis Bataille, Pascal Jézéquel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is a very heterogeneous disease, and markers for disease subtypes and therapy response remain poorly defined. For that reason, we employed a retrospective study in node-positive breast cancer to identify molecular signatures of gene expression correlating with metastatic free survival. Patients were primarily included in FEC100 (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2) arms of two multicentric prospective adjuvant clinical trials (PACS01 and PEGASE01—FNCLCC cooperative group). Data from nylon microarrays containing 8,032 cDNA unique sequences, representing 5,776 distinct genes, have been used to develop a predictive model for treatment outcome. We obtained the gene expression profiles for 150 of these patients, and used stringent univariate selection techniques based on Cox regression combined with principal component analysis to identify a genomic signature of metastatic relapse after adjuvant FEC100 regimen. Most of the 14 selected genes have a clear role in breast cancer, carcinogenesis or chemotherapy resistance. Six genes have been previously described in other genomic studies (UBE2C, CENPF, C16orf61 [DC13], STMN1, CCT5 and BCL2A1). Furthermore, we showed the interest of combining transcriptomic data with clinical data into a clinicogenomic model for patients subtyping. The described model adds predictive accuracy to that provided by the well-established Nottingham prognostic index or by our genomic signature alone.
Literatur
1.
Zurück zum Zitat Haybittle JL, Blamey RW, Elston CW et al (1982) A prognostic index in primary breast cancer. Br J Cancer 45:361–366PubMed Haybittle JL, Blamey RW, Elston CW et al (1982) A prognostic index in primary breast cancer. Br J Cancer 45:361–366PubMed
2.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef
3.
Zurück zum Zitat Eifel P, Axelson JA, Costa J et al (2001) National institutes of health consensus development conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst 93:979–989PubMedCrossRef Eifel P, Axelson JA, Costa J et al (2001) National institutes of health consensus development conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst 93:979–989PubMedCrossRef
4.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
5.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef
6.
Zurück zum Zitat van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–535CrossRef van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–535CrossRef
7.
Zurück zum Zitat van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef
8.
Zurück zum Zitat Pawitan Y, Bjöhle J, Amler L et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953–R964PubMedCrossRef Pawitan Y, Bjöhle J, Amler L et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953–R964PubMedCrossRef
9.
Zurück zum Zitat Sotiriou C, Powles TJ, Dowsett M et al (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3PubMedCrossRef Sotiriou C, Powles TJ, Dowsett M et al (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3PubMedCrossRef
10.
Zurück zum Zitat Buchholz TA, Stivers D, Stec J et al (2002) Global gene expression changes during neoadjuvant chemotherapy of human breast cancer. Cancer 8:461–468CrossRef Buchholz TA, Stivers D, Stec J et al (2002) Global gene expression changes during neoadjuvant chemotherapy of human breast cancer. Cancer 8:461–468CrossRef
11.
Zurück zum Zitat Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369PubMedCrossRef Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369PubMedCrossRef
12.
Zurück zum Zitat Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 22:2284–2293PubMedCrossRef Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 22:2284–2293PubMedCrossRef
13.
Zurück zum Zitat Gianni L (2004) Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 22:501 (Abstract) Gianni L (2004) Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 22:501 (Abstract)
14.
Zurück zum Zitat Millour M, Charbonnel C, Magrangeas F et al (2006) Gene expression profiles discriminate between pathologic complete response and resistance to neoadjuvant FEC100 in breast cancer. Cancer Genomics and Proteomics 3:89–96 Millour M, Charbonnel C, Magrangeas F et al (2006) Gene expression profiles discriminate between pathologic complete response and resistance to neoadjuvant FEC100 in breast cancer. Cancer Genomics and Proteomics 3:89–96
15.
Zurück zum Zitat Bonneterre J, Roché H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the french adjuvant study group 05 randomized trial. J Clin Oncol 23:2686–2693PubMedCrossRef Bonneterre J, Roché H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the french adjuvant study group 05 randomized trial. J Clin Oncol 23:2686–2693PubMedCrossRef
16.
Zurück zum Zitat Trudeau M, Charbonneau F, Gelman K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886–898PubMedCrossRef Trudeau M, Charbonneau F, Gelman K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886–898PubMedCrossRef
17.
Zurück zum Zitat Roché H, Viens P, Biron P et al (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10:42–47PubMed Roché H, Viens P, Biron P et al (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10:42–47PubMed
18.
Zurück zum Zitat Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the PACS01 trial. J Clin Oncol 24:5664–5671PubMedCrossRef Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the PACS01 trial. J Clin Oncol 24:5664–5671PubMedCrossRef
19.
Zurück zum Zitat Magrangeas F, Nasser V, Avet-Loiseau H et al (2003) Gene expression profiling of multiple myeloma reveals molecular portraits in realtion to the pathogenesis of the disease. Blood 101:4998–5006PubMedCrossRef Magrangeas F, Nasser V, Avet-Loiseau H et al (2003) Gene expression profiling of multiple myeloma reveals molecular portraits in realtion to the pathogenesis of the disease. Blood 101:4998–5006PubMedCrossRef
20.
Zurück zum Zitat Nevins JR, Huang ES, Dressman H et al (2003) Towards integrated clinicogenomic models for personalized medecine: combinig gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12:R153–R157PubMedCrossRef Nevins JR, Huang ES, Dressman H et al (2003) Towards integrated clinicogenomic models for personalized medecine: combinig gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12:R153–R157PubMedCrossRef
21.
Zurück zum Zitat Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332–7341PubMedCrossRef Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332–7341PubMedCrossRef
22.
Zurück zum Zitat Eden P, Ritz C, Rose C et al (2004) “Good old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837–1841PubMedCrossRef Eden P, Ritz C, Rose C et al (2004) “Good old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837–1841PubMedCrossRef
23.
Zurück zum Zitat Chirgwin JM, Przybyla AE, MacDonald RJ et al (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294–5299PubMedCrossRef Chirgwin JM, Przybyla AE, MacDonald RJ et al (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294–5299PubMedCrossRef
24.
Zurück zum Zitat Simon R, Radmacher MD, Dobbin K et al (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14–18PubMedCrossRef Simon R, Radmacher MD, Dobbin K et al (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14–18PubMedCrossRef
25.
Zurück zum Zitat Todd JH, Dowle CS, Williams MR (1987) Confirmation of prognostic index in primary breast cancer. Br J Cancer 56:489–492PubMed Todd JH, Dowle CS, Williams MR (1987) Confirmation of prognostic index in primary breast cancer. Br J Cancer 56:489–492PubMed
26.
Zurück zum Zitat Galea MH, Blamey RW, Elston CE et al (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22:207–219PubMedCrossRef Galea MH, Blamey RW, Elston CE et al (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22:207–219PubMedCrossRef
27.
Zurück zum Zitat Okamoto Y, Ozaki T, Miyazaki K et al (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 6:4167–4173 Okamoto Y, Ozaki T, Miyazaki K et al (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 6:4167–4173
28.
Zurück zum Zitat Wagner KW, Sapinoso LM, El-Rifai W et al (2004) Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23:6621–6629PubMedCrossRef Wagner KW, Sapinoso LM, El-Rifai W et al (2004) Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23:6621–6629PubMedCrossRef
29.
Zurück zum Zitat Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979PubMedCrossRef Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979PubMedCrossRef
30.
Zurück zum Zitat Rape M, Kirschner M (2004) Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432:588–595PubMedCrossRef Rape M, Kirschner M (2004) Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432:588–595PubMedCrossRef
31.
Zurück zum Zitat Ricolleau G, Charbonnel C, Lodé L et al (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6.06:1963–1975CrossRef Ricolleau G, Charbonnel C, Lodé L et al (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6.06:1963–1975CrossRef
32.
Zurück zum Zitat Hussein D, Taylor S (2002) Farnesylation of Cenp-F is required for G2/M progression and degradadtion after mitosis. J Cell Sci 115:3403–3414PubMed Hussein D, Taylor S (2002) Farnesylation of Cenp-F is required for G2/M progression and degradadtion after mitosis. J Cell Sci 115:3403–3414PubMed
33.
Zurück zum Zitat O’Brien SL, Fagan A, Fox EJP et al (2007) CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 120:1434–1443PubMedCrossRef O’Brien SL, Fagan A, Fox EJP et al (2007) CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 120:1434–1443PubMedCrossRef
34.
Zurück zum Zitat Bièche I, Lachkar S, Becette V et al (1998) Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78:701–709PubMed Bièche I, Lachkar S, Becette V et al (1998) Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78:701–709PubMed
35.
Zurück zum Zitat Curmi PA, Noguès C, Lachkar S et al (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142–150PubMedCrossRef Curmi PA, Noguès C, Lachkar S et al (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142–150PubMedCrossRef
36.
Zurück zum Zitat Brattsand G (2000) Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83:311–318PubMedCrossRef Brattsand G (2000) Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83:311–318PubMedCrossRef
37.
Zurück zum Zitat Oishi Y, Nagasaki K, Miyata S et al (2007) Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 52:271–279PubMedCrossRef Oishi Y, Nagasaki K, Miyata S et al (2007) Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 52:271–279PubMedCrossRef
38.
Zurück zum Zitat Barrett M, Pritchard D, Palanca-Wessels C et al (2003) Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett’s esophagus. Cancer Res 63:4211–4217PubMed Barrett M, Pritchard D, Palanca-Wessels C et al (2003) Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett’s esophagus. Cancer Res 63:4211–4217PubMed
39.
Zurück zum Zitat Rosty C, Sheffer M, Tsafir D et al (2005) Identification of a proliferative gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24:7094–7104PubMedCrossRef Rosty C, Sheffer M, Tsafir D et al (2005) Identification of a proliferative gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24:7094–7104PubMedCrossRef
40.
Zurück zum Zitat Milyasky M, Tabach Y, Shats I et al (2005) Transcriptional programs following genetic alterations in p53, INK4A, and H-RAS genes along defined stages of malignant transformation. Cancer Res 65:4530–4543CrossRef Milyasky M, Tabach Y, Shats I et al (2005) Transcriptional programs following genetic alterations in p53, INK4A, and H-RAS genes along defined stages of malignant transformation. Cancer Res 65:4530–4543CrossRef
41.
Zurück zum Zitat Tabach Y, Milyavsky M, Shats I et al (2005) The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol msb4100030-E1-E15 Tabach Y, Milyavsky M, Shats I et al (2005) The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol msb4100030-E1-E15
42.
Zurück zum Zitat Dai H, van’t Veer L, Lamb J et al (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer. Cancer Res 6:4059–4066CrossRef Dai H, van’t Veer L, Lamb J et al (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer. Cancer Res 6:4059–4066CrossRef
43.
Zurück zum Zitat Whitfield ML, George LK, Grant GD et al (2006) Common markers of proliferation. Nature Rev 6:99–106CrossRef Whitfield ML, George LK, Grant GD et al (2006) Common markers of proliferation. Nature Rev 6:99–106CrossRef
44.
Zurück zum Zitat Sinha P, Hutter G, Kottgen E et al (1999) Search for novel proteins involved in the devlopment of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 14:2961–2969CrossRef Sinha P, Hutter G, Kottgen E et al (1999) Search for novel proteins involved in the devlopment of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 14:2961–2969CrossRef
45.
Zurück zum Zitat Ludwig A, Dietel M, Lage M (2002) Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res 6A:3213–3221 Ludwig A, Dietel M, Lage M (2002) Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res 6A:3213–3221
46.
Zurück zum Zitat Jiang A, Zhang LX, Yue W et al (2003) Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes. Ai Zheng 4:337–345 Jiang A, Zhang LX, Yue W et al (2003) Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes. Ai Zheng 4:337–345
47.
Zurück zum Zitat Ooe A, Kato K, Noguchi S (2007) Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101:305–315PubMedCrossRef Ooe A, Kato K, Noguchi S (2007) Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101:305–315PubMedCrossRef
48.
Zurück zum Zitat Oh DS, Troester MA, Usary J et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664PubMedCrossRef Oh DS, Troester MA, Usary J et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664PubMedCrossRef
49.
Zurück zum Zitat Wang CY, Guttridge DC, Mayo MW et al (1999) NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923–5929PubMed Wang CY, Guttridge DC, Mayo MW et al (1999) NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923–5929PubMed
50.
Zurück zum Zitat Cheng Q, Ho HL, Li Y et al (2000) Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 19:4936–4940PubMedCrossRef Cheng Q, Ho HL, Li Y et al (2000) Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 19:4936–4940PubMedCrossRef
51.
Zurück zum Zitat Brown D, Alexander B, Sittman DB (1996) Differential effect of H1 variant overexpression on cell cycle progression and gene expression. Nucleic Acids Res 24:486–493PubMedCrossRef Brown D, Alexander B, Sittman DB (1996) Differential effect of H1 variant overexpression on cell cycle progression and gene expression. Nucleic Acids Res 24:486–493PubMedCrossRef
52.
Zurück zum Zitat Gunjan A, Alexander B, Sittman D et al (1999) Effects of H1 histone variant overexpression on chromatin structure. J Biol Chem 274:37950–37956PubMedCrossRef Gunjan A, Alexander B, Sittman D et al (1999) Effects of H1 histone variant overexpression on chromatin structure. J Biol Chem 274:37950–37956PubMedCrossRef
53.
Zurück zum Zitat Alami R, Fan Y, Pack S et al (2003) Mammalian linker-histone subtypes differentially affect gene expression in vivo. Proc Natl Acad Sci USA 100:5920–5925PubMedCrossRef Alami R, Fan Y, Pack S et al (2003) Mammalian linker-histone subtypes differentially affect gene expression in vivo. Proc Natl Acad Sci USA 100:5920–5925PubMedCrossRef
54.
Zurück zum Zitat Yanagawa T, Funasaka T, Tsutsumi S et al (2004) Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocrine-related Cancer 11:749–759PubMedCrossRef Yanagawa T, Funasaka T, Tsutsumi S et al (2004) Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocrine-related Cancer 11:749–759PubMedCrossRef
55.
Zurück zum Zitat Jiang WG, Raz A, Douglas-Jones A et al (2006) Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem 54:231–241PubMedCrossRef Jiang WG, Raz A, Douglas-Jones A et al (2006) Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem 54:231–241PubMedCrossRef
56.
Zurück zum Zitat Pittman J, Huang E, Dressman H et al (2004) Integrated modelling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101:8431–8436PubMedCrossRef Pittman J, Huang E, Dressman H et al (2004) Integrated modelling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101:8431–8436PubMedCrossRef
57.
Zurück zum Zitat Kattan MW (2004) Evaluating a new marker’s predictive contribution. Clin Cancer Res 10:822–824PubMedCrossRef Kattan MW (2004) Evaluating a new marker’s predictive contribution. Clin Cancer Res 10:822–824PubMedCrossRef
58.
Zurück zum Zitat Sun Y, Goodison S, Li J et al (2007) Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23:30–37PubMedCrossRef Sun Y, Goodison S, Li J et al (2007) Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23:30–37PubMedCrossRef
59.
Zurück zum Zitat Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef
60.
Zurück zum Zitat Ransohoff DE (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat Rev 5:142–149 Ransohoff DE (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat Rev 5:142–149
61.
Zurück zum Zitat Brenton JD, Carey LA, Ahmed AA et al (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23:7350–7360PubMedCrossRef Brenton JD, Carey LA, Ahmed AA et al (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23:7350–7360PubMedCrossRef
62.
Zurück zum Zitat West M, Ginsburg GS, Huang AT et al (2006) Embracing the complexity of genomic data for personalized medicine. Genome Res 16:559–566PubMedCrossRef West M, Ginsburg GS, Huang AT et al (2006) Embracing the complexity of genomic data for personalized medicine. Genome Res 16:559–566PubMedCrossRef
Metadaten
Titel
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen
verfasst von
Mario Campone
Loïc Campion
Henry Roché
Wilfried Gouraud
Catherine Charbonnel
Florence Magrangeas
Stéphane Minvielle
Jean Genève
Anne-Laure Martin
Régis Bataille
Pascal Jézéquel
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9673-x

Weitere Artikel der Ausgabe 3/2008

Breast Cancer Research and Treatment 3/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.